缺乏单段大隐静脉时膝下旁路的替代移植物结局
单中心回顾性分析2012–2023年424例慢性肢体威胁性缺血患者的480条膝下旁路,比较单段大隐静脉、肝素结合ePTFE与替代自体静脉移植物的结局。三组1年无CLTI生存无差异,但肝素结合ePTFE的3年CLTI复发率显著高于单段大隐静脉。
要点
- 缺乏合适单段大隐静脉时,替代自体静脉与肝素结合ePTFE均可用于膝下旁路
- 肝素结合ePTFE的3年CLTI复发率显著高于单段大隐静脉(45% vs 18%)
- 替代自体静脉与单段大隐静脉在3年复发、保肢、生存等方面无差异,条件允许时应优先选用
核心结论
- 缺乏合适单段大隐静脉时,替代自体静脉移植物和肝素结合ePTFE均是膝下旁路的合适选择。
- 条件允许时,替代自体静脉移植物应优先于肝素结合ePTFE。
研究设计与样本
- 单中心回顾性分析2012至2023年因慢性肢体威胁性缺血行膝下旁路的患者。
- 共424例患者、480条膝下旁路,按移植物分为单段大隐静脉、肝素结合ePTFE和替代自体静脉移植物三组。
- 中位年龄72岁(四分位距15),男性占76%(366/480),中位随访23个月(四分位距42)。
主要发现
- 总体93%(446/480)存在组织缺损,其中45%(200/446)合并一定程度感染。
- 总体1年无CLTI生存为77%,三组间无差异(校正风险比0.91,置信区间0.78-1.06,P=0.219)。
- 肝素结合ePTFE的3年CLTI复发率高于单段大隐静脉(45% vs. 18%,校正风险比3.80,置信区间1.85-7.82,P<0.001)。
- 替代自体静脉移植物与单段大隐静脉在3年CLTI复发、保肢、生存、无截肢生存、一期通畅率和三级通畅率方面均无差异。
关键数值与推荐
- 主要终点为1年无CLTI生存。
- 次要终点包括CLTI复发、保肢、生存、无截肢生存以及3年一期通畅率和三级通畅率。
- 肝素结合ePTFE组占31%(150/480),替代自体静脉移植物组占8%(38/480)。
临床怎么用
- 膝下旁路缺乏合适单段大隐静脉时,可选用替代自体静脉移植物或肝素结合ePTFE。
- 若可获取替代自体静脉移植物,应优先选择以减少3年CLTI复发。
局限性
- 单中心回顾性设计。
- 替代自体静脉移植物组样本量较小(38/480)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The aim of this study was to analyze the outcomes of patients with chronic limb threatening ischemia (CLTI) submitted to infrapopliteal (IP) bypass, using alternative conduits. METHODS: A single-center retrospective analysis of IP bypass was performed between 2012 and 2023. Patients were divided in three groups based on conduits: single-segment great saphenous vein (ssGSV), heparin-bonded expanded polytetrafluoroethylene (HePTFE), and alternative autologous venous grafts (AAVGs). The primary endpoint was 1-year freedom from CLTI. Secondary endpoints were recurrence of CLTI, limb salvage, survival, amputation-free survival (AFS), and primary patency (PP) and tertiary patency (TP) rates at 3 years of follow-up. RESULTS: A total of 480 IP bypasses were performed in 424 patients with CLTI, 31% (150/480) with HePTFE and 8% (38/480) with AAVG. Median age was 72 years (interquartile range [IQR]: 15) and 76% (366/480) were male. Median follow-up was 23 months (IQR: 42). Overall, 93% (446/480) had tissue loss, and 45% (200/446) of those had some degree of infection. One-year freedom from CLTI was achieved in 77% of the overall population, with no difference between the three groups (adjusted hazard ratio (aHR): 0.91, confidence interval [CI]: 0.78-1.06, P = 0.219). HePTFE had higher 3-year recurrence of CLTI when compared with ssGSV (45% vs. 18%, aHR: 3.80, CI: 1.85-7.82, P < 0.001). No differences were observed between ssGSV and AAVG regarding 3-year recurrence of CLTI, limb salvage, survival, AFS, PP, and TP. CONCLUSION: In the absence of an adequate ssGSV conduit, both AAVG and HePTFE grafts proved to be suitable alternatives for IP bypass. When feasible, AAVG should be preferred over HePTFE grafts.
引用
- Duarte A, Soares T, Cabral G, et al. Outcomes of Infrapopliteal Bypass With Alternative Grafts in the Absence of Single-Segment Great Saphenous Vein. Ann Vasc Surg. 2026. PMID: 41651168. doi:10.1016/j.avsg.2026.01.034
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。